{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:50:57Z","timestamp":1792511457136,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.rdc.2020.05.006","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T16:47:04Z","timestamp":1591548424000},"page":"565-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Risk Factors and Cancer Screening in Myositis"],"prefix":"10.1016","volume":"46","author":[{"given":"Siamak","family":"Moghadam-Kia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana P.","family":"Ascherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rdc.2020.05.006_bib1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/dermatomyositis and malignancy risk: a metaanalysis study","volume":"42","author":"Yang","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2020.05.006_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study","volume":"85","author":"Stockton","year":"2001","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.rdc.2020.05.006_bib3","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy. a population-based cohort study","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2020.05.006_bib4","first-page":"9","article-title":"Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark","volume":"6","author":"Chow","year":"1995","journal-title":"Cancer Causes Control"},{"issue":"6","key":"10.1016\/j.rdc.2020.05.006_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2020.05.006_bib6","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/ar2987","article-title":"Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan","volume":"12","author":"Chen","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.rdc.2020.05.006_bib7","first-page":"1855","article-title":"The overall and temporal association of cancer with polymyositis and dermatomyositis","volume":"21","author":"Zantos","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2020.05.006_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"11","key":"10.1016\/j.rdc.2020.05.006_bib9","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A\u00a0novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2020.05.006_bib10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.rdc.2020.05.006_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2133.2007.08055.x","article-title":"A\u00a0systematic review of juvenile-onset clinically amyopathic dermatomyositis","volume":"157","author":"Gerami","year":"2007","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.rdc.2020.05.006_bib12","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00296-012-2489-y","article-title":"The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis","volume":"33","author":"Limaye","year":"2013","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.rdc.2020.05.006_bib13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjd.12564","article-title":"Meta-analysis of the association of dermatomyositis and polymyositis with cancer","volume":"169","author":"Wang","year":"2013","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.rdc.2020.05.006_bib14","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3899\/jrheum.090549","article-title":"Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA","volume":"36","author":"Antiochos","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2020.05.006_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1196\/annals.1361.047","article-title":"Cancer-associated myositis: clinical features and prognostic signs","volume":"1051","author":"Ponyi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.rdc.2020.05.006_bib16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3109\/s10165-010-0362-y","article-title":"Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis","volume":"21","author":"Azuma","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2020.05.006_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000051611","article-title":"Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy","volume":"202","author":"Hunger","year":"2001","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.rdc.2020.05.006_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.50.3.191","article-title":"Polymyositis\/dermatomyositis: the current position","volume":"50","author":"Urbano-M\u00e1rquez","year":"1991","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2020.05.006_bib19","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archderm.138.7.885","article-title":"Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients","volume":"138","author":"Sparsa","year":"2002","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2020.05.006_bib20","first-page":"438","article-title":"Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study","volume":"35","author":"Andr\u00e1s","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2020.05.006_bib21","first-page":"722","article-title":"[Prognostic factors and predictive signs of malignancy in adult dermatomyositis]","volume":"123","author":"Gallais","year":"1996","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.rdc.2020.05.006_bib22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1468-3083.2008.02971.x","article-title":"Clinical and biological factors predictive of malignancy in dermatomyositis","volume":"23","author":"Prohic","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.rdc.2020.05.006_bib23","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1046\/j.1365-4362.1997.00190.x","article-title":"Malignancy in adult dermatomyositis","volume":"36","author":"Leow","year":"1997","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.rdc.2020.05.006_bib24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archderm.1990.01670290077012","article-title":"Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases","volume":"126","author":"Basset-Seguin","year":"1990","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2020.05.006_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.semarthrit.2015.06.005","article-title":"Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort","volume":"45","author":"Dobloug","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2020.05.006_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10067-016-3453-0","article-title":"Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis","volume":"36","author":"Ceribelli","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2020.05.006_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12016-015-8511-x","article-title":"Idiopathic inflammatory myopathies and malignancy: a comprehensive review","volume":"52","author":"Tiniakou","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.rdc.2020.05.006_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.rdc.2020.05.006_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40257-016-0199-z","article-title":"Amyopathic dermatomyositis: a concise review of clinical manifestations and associated malignancies","volume":"17","author":"Udkoff","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"10.1016\/j.rdc.2020.05.006_bib30","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/ard.2006.068502","article-title":"The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis","volume":"66","author":"Chinoy","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2020.05.006_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140\u00a0kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2020.05.006_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MD.0b013e3181ca14ff","article-title":"Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy","volume":"89","author":"Trallero-Aragu\u00e1s","year":"2010","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.rdc.2020.05.006_bib33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2020.05.006_bib34","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2020.05.006_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2020.05.006_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"issue":"Pt 8","key":"10.1016\/j.rdc.2020.05.006_bib37","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.rdc.2020.05.006_bib38","first-page":"1","article-title":"Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level","volume":"5","author":"Aggarwal","year":"2019","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2020.05.006_bib39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.rdc.2020.05.006_bib40","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jaad.2018.11.023","article-title":"Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis","volume":"80","author":"Hoesly","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2020.05.006_bib41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.semarthrit.2019.04.002","article-title":"Immune-mediated necrotising myopathy: a critical review of current concepts","volume":"49","author":"Day","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2020.05.006_bib42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00005792-199405000-00004","article-title":"Ovarian cancer in patients with dermatomyositis","volume":"73","author":"Whitmore","year":"1994","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.rdc.2020.05.006_bib43","first-page":"1897","article-title":"Dermatomyositis and ovarian cancer: a report of 7 cases and literature review","volume":"20","author":"Cherin","year":"1993","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2020.05.006_bib44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/gyno.1997.4666","article-title":"Serum CA-125 screening for ovarian cancer in patients with dermatomyositis","volume":"65","author":"Whitmore","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.rdc.2020.05.006_bib45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1158\/1055-9965.EPI-04-0624","article-title":"Tumor antigen markers for the detection of solid cancers in inflammatory myopathies","volume":"14","author":"Amoura","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.rdc.2020.05.006_bib46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00124743-200208000-00005","article-title":"Transient elevation of the tumor markers CA 15-3 and CASA as markers of interstitial lung disease rather than underlying malignancy in dermatomyositis sine myositis","volume":"8","author":"Wong","year":"2002","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2020.05.006_bib47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.amjmed.2009.11.012","article-title":"Conventional cancer screening versus PET\/CT in dermatomyositis\/polymyositis","volume":"123","author":"Selva-O'Callaghan","year":"2010","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.rdc.2020.05.006_bib48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MNM.0000000000000981","article-title":"18F-FDG PET\/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications","volume":"40","author":"Maliha","year":"2019","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1016\/j.rdc.2020.05.006_bib49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.semarthrit.2018.10.021","article-title":"Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis","volume":"49","author":"Kundrick","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2020.05.006_bib50","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.3899\/jrheum.111597","article-title":"Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis","volume":"39","author":"Owada","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2020.05.006_bib51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/1346-8138.14758","article-title":"Clinical value of (18) F-fluorodeoxyglucose positron emission tomography\/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis","volume":"46","author":"Motegi","year":"2019","journal-title":"J\u00a0Dermatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X20300582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X20300582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:18:25Z","timestamp":1760181505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X20300582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0889857X20300582"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2020.05.006","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors and Cancer Screening in Myositis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2020.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}